Eli Lilly Announces Phase III Data for Retatrutide: 28.3% Weight Loss and Significant Systemic Anti-Inflammatory Effects, Ushering in the Triple-Target Era in GLP-1 Therapy
May 21,2026
Eli Lilly released full Phase III results for retatrutide, the world's first GLP-1/GIP/GCG triple receptor agonist.
Key efficacy data (80 weeks):
- 12 mg group: 28.3% mean weight loss (~31.9 kg) ; 45.3% lost >30% of body weight; 27.2% lost >35%.
- 9 mg group: 25.9% (~29.2 kg); 4 mg group: 19.0% (~19 kg); placebo: 2.2%.
- In severe obesity (BMI ≥35), extended follow-up (104 weeks) showed 30.3% peak weight loss (~38.5 kg fat loss) with no plateau effect.
First-ever systematic anti-inflammatory effect:
Retatrutide significantly suppressed chronic low-grade systemic inflammation, reducing hs-CRP, IL-6, and TNF-α. Some participants saw hs-CRP drop from high-risk to healthy levels as early as week 12. The anti-inflammatory effect is mediated via synergistic GLP-1, GIP, and GCG pathways, independent of weight loss alone.
Additional benefits:
- Knee pain complete resolution in osteoarthritis: 12.0% (12 mg) and 14.1% (9 mg) vs. 4.2% (placebo).
- Mean systolic blood pressure reduction: 14 mmHg.
- Improved triglycerides and LDL cholesterol.
Safety:
Mainly gastrointestinal discomfort during dose escalation, generally manageable.
Regulatory pathway:
Not yet approved. Lilly plans to submit NDA for obesity to the U.S. FDA in H2 2026, followed by T2D in early 2027. Potential approval as early as mid-2027 (priority review) or late 2027–early 2028 (standard review).
Significance:
Retatrutide moves obesity treatment beyond simple weight reduction toward a comprehensive model integrating weight management, systemic inflammation repair, and multi-organ metabolic protection—officially opening the triple-target era in GLP-1 therapy.
Remark: This content is AI-generated and for reference only. It is compiled from online sources. Please refer to official information for accuracy.
Syntame Exhibition Tour 2026
CPHI China 2026 Concludes Successfully | Shentai Bio Will Continue to Focus on High-Content Pharmaceutical Raw Material Solutions
CPHI South East Asia 2025 comes to a successful conclusion | SYNTAME opens a new chapter in the Southeast Asian market
CPHI China 2025 ended successfully | Syntame talks with customers around the world about new opportunities for cooperation
The company team made a stunning appearance at the 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI) at the Shanghai New International Expo Centre.
No.298 Mingguang Road, Urban Industrial Park, Yinzhou District, Ningbo City, Zhejiang Province, P.R. China
